chufangao/CTO huggingface dataset:
Clinical trial NCT04338126: Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
Official title: Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients
Acronym: TCInpatient
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to ongoing vaccination efforts, feasibility for recruitment is low
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-30
Primary completion date: 2021-12-15
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Official title: A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX)
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-01-18
Primary completion date: 2024-08-20
Completion date: 2024-08-20
Plan to share individual participant data: NO
IPD sharing description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Clinical trial NCT04931667: 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
Official title: A 3-Year, Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Intra-articular Lorecivivint in Subjects With Osteoarthritis of the Knee in a Real-World Setting (STRIDES-EXTRA)
Sponsor: Biosplice Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated due to business reasons by Sponsor.
Enrollment: 73.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-07-15
Primary completion date: 2021-12-13
Completion date: 2021-12-13
Plan to share individual participant data: NO
Clinical trial NCT03618953: This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
Official title: Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers
Acronym: Kingfisher
Sponsor: Turnstone Biologics, Corp. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Virus potency titer of drug product as determined by an improved potency assay was lower than originally determined by the assay described in the IND.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-21
Primary completion date: 2021-03-05
Completion date: 2021-03-05
Clinical trial NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
Official title: An Open-label, Nonrandomized, Phase 3 Study to Evaluate the Efficacy and Safety of Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision unrelated to patient safety.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-04-25
Primary completion date: 2024-08-14
Completion date: 2024-08-14
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT02767232: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
Official title: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
Acronym: PHLO
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Did not receive NIH Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-31
Primary completion date: 2023-04-30
Completion date: 2023-06-30
Clinical trial NCT04351516: Test and Treat COVID 65plus+
Official title: Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients
Acronym: COVID65plus
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: No Patients enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-21
Primary completion date: 2020-12-31
Completion date: 2021-05-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04276883: Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Official title: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder
Acronym: SERENITY II
Sponsor: BioXcel Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 380.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-02-24
Primary completion date: 2020-05-21
Completion date: 2020-05-21
Baseline population: Safety population (all participants who received study drug)
Clinical trial NCT03265080: A Study of ADXS-NEO Expressing Personalized Tumor Antigens
Official title: A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Acronym: NEO
Sponsor: Advaxis, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-28
Primary completion date: 2019-10-24
Completion date: 2020-11-12
Plan to share individual participant data: NO
Clinical trial NCT02329756: Tranexamic Acid in Adherent Placenta (TAP)
Official title: Tranexamic Acid in Adherent Placenta (TAP), a Randomized Clinical Trial
Sponsor: Baylor College of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: More preparation needed prior to collecting data.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-31
Primary completion date: 2020-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02753283: Preventing Osteoporosis Using Denosumab
Official title: Sustaining Skeletal Health in Frail Elderly
Acronym: PROUD
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-06-30
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT03605238: Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20
Official title: Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD)
Sponsor: Chinese PLA General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: It was hard to recruit patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-15
Primary completion date: 2019-08-15
Completion date: 2020-08-15
Plan to share individual participant data: NO
Clinical trial NCT03601637: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
Official title: A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-07
Primary completion date: 2021-10-29
Completion date: 2021-10-29
Baseline population: All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis. The baseline analysis was collected for the overall treatment arm, irrespective of a weight-based dose regimen. Therefore, the analysis is reported in a single arm for each study part (Part A: LUM/IVA and Part B: LUM/IVA).
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT02030184: Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Official title: Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: PI has left the study institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2019-06-30
Completion date: 2021-06-30
Clinical trial NCT03340727: Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial
Official title: Randomized Controlled Trial of Home Therapy With Caffeine Citrate in Moderately Preterm Infants With Apnea of Prematurity
Acronym: MoCHA
Sponsor: NICHD Neonatal Research Network (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Futility
Enrollment: 827.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-27
Primary completion date: 2023-01-23
Completion date: 2023-03-20
Baseline population: The study recruited infants based on eligibility and parental/guardian consent. Baseline characteristics of the mother were collected (with consent) for use in statistical analysis.
Plan to share individual participant data: YES
IPD sharing description: Per NIH Data Sharing Plan
Clinical trial NCT03432897: BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes
Official title: BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes
Acronym: 337
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment secondary to eligibility criteria
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-25
Primary completion date: 2020-12-15
Completion date: 2021-12-07
Plan to share individual participant data: NO
Clinical trial NCT03150836: Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
Official title: Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-10-01
Primary completion date: 2021-09-01
Completion date: 2024-09-01
Plan to share individual participant data: NO
Clinical trial NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Official title: An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to the sponsor's research and development strategy adjustment.
Enrollment: 86.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-22
Primary completion date: 2023-07-26
Completion date: 2023-07-26
Plan to share individual participant data: NO
Clinical trial NCT04668339: A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
Official title: A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants
Sponsor: Arcturus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.
Enrollment: 581.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-01-07
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Plan to share individual participant data: NO
IPD sharing description: Individual participant data will only be made available to study investigators at this time.
Clinical trial NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Official title: Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Industry sponsor decision
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-03
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Limitations and caveats: Enrollment was closed earlier than expected due to industry sponsor's prioritization of other programs, the termination of Varliumab development, and Coronavirus disease of 2019 (COVID-19) related challenges during the period of enrollment. Appropriate reagents were not available for the CD4+ outcome measure. Due to the small number of participants, the biological/immunological evaluations are insufficiently powered to provide meaningful statistical significance.
Plan to share individual participant data: NO
Clinical trial NCT04915352: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
Official title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
Acronym: NPT-MAR
Sponsor: Centre Hospitalier Régional Metz-Thionville (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study is terminated because the product (nasal provocation test) is out of stock.
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-07
Primary completion date: 2024-07-05
Completion date: 2024-07-05
Plan to share individual participant data: NO
Clinical trial NCT03542812: L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia
Official title: Pharmacokinetics of L-citrulline in Infants at High Risk of Developing Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The study stopped enrollment prior to the initially projected 18 subjects per phase due to lack of funding to continue to recertify the drug and because an adequate number of subjects were enrolled for each phase to analyze pharmacokinetics.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-30
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Limitations and caveats: The study was terminated prior to full enrollment goals of group 3 (steady-state group), therefore there was a small number of subjects for analysis.
Plan to share individual participant data: NO
Clinical trial NCT03196947: Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
Official title: Phase I, Open Label, Dose Escalation Study to Investigate the Tolerability and Efficacy of APO010 in Patients With Relapsed/Refractory Multiple Myeloma Selected by Drug Response Predictor (DRP)
Acronym: SMR-3184
Sponsor: Allarity Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early due to sponsors decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-13
Primary completion date: 2020-01-16
Completion date: 2020-01-16
Clinical trial NCT02684578: Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Official title: METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
Acronym: METforMIN
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2022-04-30
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT04646109: Ivermectin for Severe COVID-19 Management
Official title: The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management
Sponsor: Afyonkarahisar Health Sciences University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-11
Primary completion date: 2020-09-02
Completion date: 2020-09-02
Baseline population: 36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.
Plan to share individual participant data: NO
Clinical trial NCT03933956: Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Official title: Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Acronym: (MEDiaN)
Sponsor: Singapore General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study terminated owing to challenges posed by the COVID-19 situation.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-09
Primary completion date: 2020-08-01
Completion date: 2020-08-01
Plan to share individual participant data: NO
Clinical trial NCT01860976: Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
Official title: A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Acronym: ASTRAEA
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 489.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-06-17
Primary completion date: 2015-07-14
Completion date: 2020-06-30
Baseline population: All randomized participants
Clinical trial NCT03897088: Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Official title: A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp
Sponsor: Sun Pharmaceutical Industries Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 231.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-29
Primary completion date: 2022-02-17
Completion date: 2022-02-17
Plan to share individual participant data: NO
Clinical trial NCT03486912: A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
Official title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
Acronym: FALCON 2
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 155.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-06-12
Primary completion date: 2020-10-08
Completion date: 2021-09-14
Clinical trial NCT03096834: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
Official title: A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous 140 mg AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed 2-4 Prophylactic Treatments (LIBERTY)
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 246.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-03-20
Primary completion date: 2018-01-18
Completion date: 2021-01-28
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04154033: Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
Official title: Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone as Well as the Influence of Circadian Rhythm
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-01
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Plan to share individual participant data: NO